Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

11.25
+1.6116.70%
Post-market: 11.350.1000+0.89%19:58 EDT
Volume:1.51M
Turnover:16.45M
Market Cap:513.86M
PE:-9.79
High:11.32
Open:10.20
Low:10.20
Close:9.64
Loading ...

Capricor Therapeutics Completes Submission Of Biologics License Application To The U.S. FDA For Deramiocel

T-Reuters
·
02 Jan

Capricor Therapeutics - Bla Submission Triggers $10 Mln Milestone Payment to Capricor From Nippon Shinyaku

THOMSON REUTERS
·
02 Jan

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
02 Jan

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Dow Jones
·
13 Dec 2024

Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk

Dow Jones
·
12 Dec 2024

Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding

Simply Wall St.
·
12 Dec 2024

Capricor unlikely impacted by Phan warning letter, says JonesResearch

TIPRANKS
·
06 Dec 2024

Stock Track | Capricor Therapeutics Soars 5.87% as Oppenheimer Reiterates Buy Rating

Stock Track
·
21 Nov 2024

Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
21 Nov 2024

Stock Track | Capricor Therapeutics Soars 5.04% on EU Designations for Lead Asset Deramiocel

Stock Track
·
21 Nov 2024

Capricor Gets Orphan Drug, Advanced Therapy Medicinal Product Designations for Deramiocel in Europe

MT Newswires Live
·
20 Nov 2024

BRIEF-Capricor Therapeutics Granted Orphan Drug And ATMP Status For Deramiocel By European Medicines Agency

Reuters
·
20 Nov 2024

Capricor Therapeutics Inc - Expects to Complete Bla Submission by End of 2024

THOMSON REUTERS
·
20 Nov 2024

Capricor Therapeutics Granted Orphan Drug and Atmp Status for Deramiocel by European Medicines Agency

THOMSON REUTERS
·
20 Nov 2024

JonesTrading Initiates Capricor Therapeutics at Buy Rating With $40 Price Target

MT Newswires Live
·
18 Nov 2024

U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals

Reuters
·
18 Nov 2024

Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?

Insider Monkey
·
16 Nov 2024

Capricor Therapeutics: Promising Developments and Strong Financial Position Drive Buy Rating

TIPRANKS
·
16 Nov 2024

Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
15 Nov 2024

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024